Magaldrate
Magaldrate (INN) is a common antacid drug that is used for the treatment of duodenal and gastric ulcers, esophagitis from gastroesophageal reflux.
| Clinical data | |
|---|---|
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| MedlinePlus | a682683 |
| Pregnancy category |
|
| Routes of administration | Oral |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | Negligible |
| Metabolism | Nil |
| Excretion | Fecal and renal |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.115.465  |
| Chemical and physical data | |
| Formula | AlMg2(OH)7·H2O |
| Molar mass | 212.66 g/mol |
| |
| (verify) | |
Development
Magaldrat was first synthesized by the German chemist Gunther Hallmann and patented on February 2, 1960 by Byk Gulden Lomberg Chemische Fabrik (Germany).[1] In 1983, the active substance was registered as the original drug Riopan.[2]
Available forms
Magaldrate is available in the form of oral suspension or tablets.
Pharmacology
Magaldrate is a hydroxymagnesium aluminate complex that is converted rapidly by gastric acid into Mg(OH)2 and Al(OH)3, which are absorbed poorly and thus provide a sustained antacid effect.[3]
Interactions and adverse reactions
Magaldrate may negatively influence drugs like tetracyclines, benzodiazepines, and indomethacin. High doses or prolonged usage may lead to an increment of defecation and a reduction in feces consistence. In some cases it can alter the functionality of the gastrointestinal tract, occasionally provoking constipation or diarrhea.
References
- US patent 2923660, Gunther Hallmann, "Process for the preparation of magnesium aluminate hydrate, and therapeutic agents so produced", issued 1960-02-02, assigned to Byk Gulden Lomberg Chem. Fab.
- Fachinfo Riopan Magen Tabletten, Stand Dezember 2014.
- Laurence L., Brunton. Goodman & Gilman's The Pharmacological Basis of Therapeutics, 12th ed.